ArriVent BioPharma (AVBP) PT Raised to $36 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
ArriVent BioPharma (AVBP) PT Raised to $36 at Citi
September 10, 2024 11:49 AM EDTCiti analyst Yigal Nochomovitz raised the price target on ArriVent BioPharma (NASDAQ: AVBP) to $36.00 (from $30.00) while maintaining a Buy rating.
The analyst comments "Today, AVBP shared data from the Ph1b FURTHER study evaluating firmonertinib in 1L+ EGFR PACC mutations at WCLC. The... More
